Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 48c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $243.84 +0.10%
EPS Growth %: -20.4%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -20.4%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $3.90, $0.48 better than the analyst estimate of $3.42. Revenue for the quarter came in at $751.8 million versus the consensus estimate of $735.62 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2021 EPS of $13.40-$14.70, versus the consensus of $14.45. Jazz Pharmaceuticals sees FY2021 revenue of $3.02-3.18 billion, versus the consensus of $3.11 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Intuit holds investor day, reaffirms fiscal 2027 guidance
- Piper Sandler Reiterates Overweight Rating on Block Inc. (XYZ)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
